Phase II randomized controlled trial to evaluate the efficacy and safety of HeberFERON versus Heberon alpha R in symptomatic or asymptomatic patients infected with the SARS-CoV-2 (Study ESPERANZA/HOPE).
Bello-Rivero Iraldo, Gerardo Guillén(Hunan City University), Verena L. Muzio‐González(Centro de Ingeniería Genética y Biotecnología), Claudia Martínez Suarez, Hugo Nodarse-Cuní, Yaquelín Duncan-Roberts, Idelsis Esquivel-Moy(Hospital Militar Central), Francisco Hernández‐Bernal(Centro de Ingeniería Genética y Biotecnología), Ivan Campa-Legrá(Centro de Ingeniería Genética y Biotecnología)
Cited by 0
Related Papers
Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications
|International Wound Journal|2009|167
A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial
|Annals of Oncology|1998|155
Glucose Toxic Effects on Granulation Tissue Productive Cells: The Diabetics’ Impaired Healing
|BioMed Research International|2012|153
Wound Chronicity, Impaired Immunity and Infection in Diabetic Patients
|MEDICC Review|2021|139
Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review
|Frontiers in Endocrinology|2020|134